We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine

Scaling human pluripotent stem cell expansion and differentiation: are cell factories becoming a reality?

    James GW Smith

    Wolfson Centre for Stem Cells, Tissue Engineering & Modelling Centre for Biomolecular Sciences, University of Nottingham, Nottingham, NG7 2RD, UK

    ,
    Adam D Celiz

    Laboratory of Biophysics & Surface Analysis, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK

    Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA

    ,
    Asha K Patel

    Wolfson Centre for Stem Cells, Tissue Engineering & Modelling Centre for Biomolecular Sciences, University of Nottingham, Nottingham, NG7 2RD, UK

    David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

    ,
    Robert D Short

    Mawson Institute, University of South Australia, Adelaide, SA 5001, Australia

    ,
    Morgan R Alexander

    Laboratory of Biophysics & Surface Analysis, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK

    &
    Chris Denning

    Wolfson Centre for Stem Cells, Tissue Engineering & Modelling Centre for Biomolecular Sciences, University of Nottingham, Nottingham, NG7 2RD, UK

    Published Online:https://doi.org/10.2217/rme.15.65
    Free first page

    References

    • 1 Bretzner F, Gilbert F, Baylis F, Brownstone RM. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell 8(5), 468–475 (2011).
    • 2 Schwartz SD, Regillo CD, Lam BL et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label Phase 1/2 studies. Lancet 385(9967), 509–516 (2015).
    • 3 Menasche P, Vanneaux V, Hagege A et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur. Heart J. 36(30), 2011–2017 (2015).
    • 4 Reardon S, Cyranoski D. Japan stem-cell trial stirs envy. Nature 513(7518), 287–288 (2014).
    • 5 Nguyen HV, Li Y, Tsang SH. Patient-specific iPSC-derived RPE for modeling of retinal diseases. J. Clin. Med. 4(4), 567–578 (2015).
    • 6 Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8(1), 30–41 (2011).
    • 7 Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 282(5391), 1145–1147 (1998).
    • 8 Joannides A, Fiore-Heriche C, Westmore K et al. Automated mechanical passaging: a novel and efficient method for human embryonic stem cell expansion. Stem Cells 24(2), 230–235 (2006).
    • 9 Tannenbaum SE, Turetsky TT, Singer O et al. Derivation of xeno-free and GMP-grade human embryonic stem cells – platforms for future clinical applications. PLoS ONE 7(6), e35325 (2012).
    • 10 Xu C, Inokuma MS, Denham J et al. Feeder-free growth of undifferentiated human embryonic stem cells. Nat. Biotechnol. 19(10), 971–974 (2001).
    • 11 Miyazaki T, Futaki S, Hasegawa K et al. Recombinant human laminin isoforms can support the undifferentiated growth of human embryonic stem cells. Biochem. Biophys. Res. Commun. 375(1), 27–32 (2008).
    • 12 Nagaoka M, Si-Tayeb K, Akaike T, Duncan SA. Culture of human pluripotent stem cells using completely defined conditions on a recombinant E-cadherin substratum. BMC Dev. Biol. doi:10.1186/1471-213X-10-60 (2010) (Epub ahead of print).
    • 13 Celiz AD, Smith JG, Langer R et al. Materials for stem cell factories of the future. Nat. Mat. 13(6), 570–579 (2014).
    • 14 Mahlstedt MM, Anderson D, Sharp JS et al. Maintenance of pluripotency in human embryonic stem cells cultured on a synthetic substrate in conditioned medium. Biotechnol. Bioeng. 105(1), 130–140 (2010).
    • 15 Celiz AD, Smith JG, Patel AK et al. Discovery of a novel polymer for human pluripotent stem cell expansion and multilineage differentiation. Adv. Mat. 27(27), 4006–4012 (2015).
    • 16 Amit M, Shariki C, Margulets V, Itskovitz-Eldor J. Feeder layer- and serum-free culture of human embryonic stem cells. Biol. Reprod. 70(3), 837–845 (2004).
    • 17 Ludwig TE, Levenstein ME, Jones JM et al. Derivation of human embryonic stem cells in defined conditions. Nat. Biotechnol. 24(2), 185–187 (2006).
    • 18 Chen G, Gulbranson DR, Hou Z et al. Chemically defined conditions for human iPSC derivation and culture. Nat. Methods 8(5), 424–429 (2011).
    • 19 Rodin S, Antonsson L, Niaudet C et al. Clonal culturing of human embryonic stem cells on laminin-521/E-cadherin matrix in defined and xeno-free environment. Nat. Commun. 5, 3195 (2014).
    • 20 Aguilar JS, Begum AN, Alvarez J, Zhang XB, Hong Y, Hao J. Directed cardiomyogenesis of human pluripotent stem cells by modulating Wnt/beta-catenin and BMP signalling with small molecules. Biochem. J. 469(2), 235–241 (2015).
    • 21 Hay DC, Pernagallo S, Diaz-Mochon JJ et al. Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism. Stem Cell Res. 6(2), 92–102 (2011).
    • 22 Patel AK, Celiz AD, Rajamohan D et al. A defined synthetic substrate for serum-free culture of human stem cell derived cardiomyocytes with improved functional maturity identified using combinatorial materials microarrays. Biomaterials 61, 257–265 (2015).
    • 23 Matsuura K, Masuda S, Haraguchi Y et al. Creation of mouse embryonic stem cell-derived cardiac cell sheets. Biomaterials 32(30), 7355–7362 (2011).
    • 24 Boheler KR, Joodi RN, Qiao H et al. Embryonic stem cell-derived cardiomyocyte heterogeneity and the isolation of immature and committed cells for cardiac remodeling and regeneration. Stem Cells Int. 2011, 214203 (2011).
    • 25 Chong JJ, Yang X, Don CW et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510(7504), 273–277 (2014).
    • 26 Paull D, Sevilla A, Zhou H et al. Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat. Methods doi:10.1038/nmeth.3507 (2015) (Epub ahead of print).
    • 27 Elanzew A, Sommer A, Pusch-Klein A, Brustle O, Haupt S. A reproducible and versatile system for the dynamic expansion of human pluripotent stem cells in suspension. Biotechnol. J. doi:10.1002/biot.201400757 (2015) (Epub ahead of print).
    • 28 Kempf H, Olmer R, Kropp C et al. Controlling expansion and cardiomyogenic differentiation of human pluripotent stem cells in scalable suspension culture. Stem Cell Rep. 3(6), 1132–1146 (2014).
    • 29 Pennington BO, Clegg DO, Melkoumian ZK, Hikita ST. Defined culture of human embryonic stem cells and xeno-free derivation of retinal pigmented epithelial cells on a novel, synthetic substrate. Stem Cells Transl. Med. 4(2), 165–177 (2015).
    • 30 Simaria AS, Hassan S, Varadaraju H et al. Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies. Biotechnol. Bioeng. 111(1), 69–83 (2014).